Test Page (do not delete)

December 2023

GRASP Reception Registration

Attending the 2023 San Antonio Breast Cancer Symposium (SABCS) in person? Join us for a reception bringing together scientists and patient advocates. All advocates, scientists, and partners are invited to connect and mingle in person at this fun event put on by GRASP, a new tradition at SABCS! The event will take place on-site at […] ...
05 Dec
6:30 pm - 8:00 pm

SABCS23 GRASP Training

Join us for a training session so that you can be prepared for your upcoming event. Whether joining as a GRASP scientist, poster author, mentor, or patient advocate, these sessions will help you understand your respective role. ...
12 Dec
7:00 pm - 8:00 pm

San Antonio Breast Cancer Symposium (SABCS23)

The 2023 San Antonio Breast Cancer Symposium (SABCS) will be held on December 5-9, 2023. This year’s SABCS conference will be held as a hybrid conference with both in-person events and live web streaming. The Symposium aims to achieve a balance of clinical, translational, and basic research, providing a forum for interaction, communication, and education for a […] ...
14 - 15 Dec
10:00 am - 7:30 pm

Group 1B: HER2-low, HER2-0, & HR+ Breast Cancer; Clinical Trials Sold Out

Poster #PO1-05-12: Pooled clinical trial data analyses comparing the biology of HER2-low vs HER2-0 breast cancer in patients with metastatic breast cancer following treatment with standard single agent chemotherapy. Poster #PO2-20-02: A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/ HER2- advanced breast cancer previously treated with a […] ...
14 Dec
10:00 am - 11:30 am

Group 1C: BRCA+ Breast Cancer; Clinical Trials; Oncofertility; Younger Populations

Poster #PO2-11-06: Anti-Müllerian hormone in Young women with breast CAncer to predict permanent loss of ovarian function after chemotherapy and anti-HER2 therapy (AMYCA): a biomarker analysis of the BETH and KAITLIN trials. Poster #PO1-06-09: Phase 2 Trial with safety run-in of gedatolisib plus talazoparib in advanced triple negative or BRCA1/2+, HER2-negative breast cancers Big Ten […] ...
14 Dec
10:00 am - 11:30 am

Group 1D: Brain Metastasis; Novel Targets

Poster #PS11-06: Analysis of HER2 expression changes from breast primary to brain metastases including HER2 Low and impact on overall survival. Poster #PO3-06-12: Targeting fatty acid synthase in brain metastatic triple-negative breast cancer. ...
14 Dec
10:00 am - 11:30 am

Group 2A: Lobular Breast Cancer; Imaging Sold Out

Poster #PO2-07-09: Early stage invasive lobular breast cancer is underestimated on conventional imaging including MRI. Poster #PO4-02-12: MDA iLobular prognostic pool: A novel approach for risk stratification in invasive lobular carcinoma. ...
14 Dec
2:00 pm - 3:30 pm

Group 2B: Triple Negative Breast Cancer; Clinical Trials; Side Effects

Poster #PO2-12-12: REaCT 5G: A randomized study comparing bone pain after 5 days of filgrastim or one day of pegfilgrastim for primary febrile neutropenia prophylaxis during neo-/adjuvant chemotherapy for early breast cancer. Poster #PO1-18-07: Phase I trial of combination pembrolizumab and ruxolitinib in metastatic triple negative breast cancer. ...
14 Dec
2:00 pm - 3:30 pm
No event found!
Load More


Sep 23 2023


8:00 am - 6:00 pm